English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/63297
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Chromenopyrazoles: Non-psychoactive and Selective CB 1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

AuthorsCumella Montánchez, José María ; Hernández-Folgado, Laura ; Gómez-Cañas, M.; Girón, Rocío; Sánchez, E.; Morales, Paula ; Hurst, D. P.; Gómez-Cañas, M.; Gómez-Ruiz, M.; Pinto, Diana C. G. A.; Goya, Pilar ; Reggio, P. H.; Martín, M. Isabel ; Fernández-Ruiz, Javier; Silva, Artur M. S.; Jagerovic, Nadine
Issue Date2012
PublisherWiley-VCH
CitationChemMedChem 7: 452- 463 (2012)
AbstractThe unwanted psychoactive effects of cannabinoid receptor agonists have limited their development as medicines. These CB 1-mediated side effects are due to the fact that CB 1 receptors are largely expressed in the central nervous system (CNS). As it is known that CB 1 receptors are also located peripherally, there is growing interest in targeting cannabinoid receptors located outside the brain. A library of chromenopyrazoles designed analogously to the classical cannabinoid cannabinol were synthesized, characterized, and tested for cannabinoid activity. Radioligand binding assays were used to determine their affinities at CB 1 and CB 2 receptors. Structural features required for CB 1/CB 2 affinity and selectivity were explored by molecular modeling. Some compounds in the chromenopyrazole series were observed to be selective CB 1 ligands. These modeling studies suggest that full CB 1 selectivity over CB 2 can be explained by the presence of a pyrazole ring in the structure. The functional activities of selected chromenopyrazoles were evaluated in isolated tissues. Invivo behavioral tests were then carried out on the most effective CB 1 cannabinoid agonist, 13a. Chromenopyrazole 13a did not induce modifications in any of the tested parameters on the mouse cannabinoid tetrad, thus discounting CNS-mediated effects. This lack of agonistic activity in the CNS suggests that this compound does not readily cross the blood-brain barrier. Moreover, 13a can induce antinociception in a rat peripheral model of orofacial pain. Taking into account the negative results obtained with the hot-plate test, the antinociception induced by 13a in the orofacial test could be mediated through peripheral mechanisms. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
URIhttp://hdl.handle.net/10261/63297
DOI10.1002/cmdc.201100568
Identifiersdoi: 10.1002/cmdc.201100568
issn: 1860-7179
e-issn: 1860-7187
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.